Outlook for Novo Nordisk is pretty bright, says Yuri Khodjamirian

Поделиться
HTML-код
  • Опубликовано: 1 май 2024
  • Yuri Khodjamirian CIO tema etfs

Комментарии • 2

  • @raizyandrei1268
    @raizyandrei1268 Месяц назад +2

    Good data bring the stock down..so it is working this days😂

  • @mortenrobinson5421
    @mortenrobinson5421 Месяц назад

    Investors whom are worried about the high p/e. Remember, this is the medical industry and Novo Nordisk and Eli Lilly are the two giants. Drugs to treat obesity is just one category of drugs that these companies manufacture, but so long as we haven't cured all deceases and ailments, there will still be plenty of growth within this industry. The high P/E for stocks in this industry is not totally unjustified, but Novo's P/E is much lower than that of Eli Lilly.